Samarth Kulkarni Sells 25,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total transaction of $1,897,750.00. Following the transaction, the chief executive officer now directly owns 290,279 shares of the company’s stock, valued at approximately $22,035,078.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

  • On Wednesday, June 29th, Samarth Kulkarni sold 25,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $61.59, for a total transaction of $1,539,750.00.

CRISPR Therapeutics Trading Down 1.2 %

CRSP opened at $75.00 on Friday. The firm has a market capitalization of $5.81 billion, a PE ratio of 20.78 and a beta of 1.91. CRISPR Therapeutics AG has a twelve month low of $42.51 and a twelve month high of $142.64. The firm’s 50-day moving average price is $68.36 and its 200 day moving average price is $62.68.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last posted its quarterly earnings results on Monday, May 9th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.91) by ($0.41). The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $2.45 million. CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The business’s revenue was up 74.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.51) earnings per share. As a group, analysts predict that CRISPR Therapeutics AG will post -8.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CRSP has been the subject of several recent research reports. Needham & Company LLC reduced their target price on shares of CRISPR Therapeutics from $170.00 to $122.00 in a report on Friday, May 13th. Barclays cut their price objective on shares of CRISPR Therapeutics from $107.00 to $99.00 in a report on Tuesday, May 10th. Credit Suisse Group started coverage on shares of CRISPR Therapeutics in a report on Thursday, April 28th. They issued a “neutral” rating and a $78.00 price objective for the company. Oppenheimer cut their price objective on shares of CRISPR Therapeutics from $150.00 to $122.00 and set an “outperform” rating for the company in a report on Thursday, June 23rd. Finally, Citigroup cut their price objective on shares of CRISPR Therapeutics from $64.00 to $53.00 and set a “neutral” rating for the company in a report on Tuesday, May 17th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $114.31.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CRSP. Capital Impact Advisors LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth about $26,000. Elkhorn Partners Limited Partnership boosted its position in CRISPR Therapeutics by 180.0% during the fourth quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock worth $27,000 after acquiring an additional 225 shares during the last quarter. IronBridge Private Wealth LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth about $30,000. First PREMIER Bank acquired a new position in CRISPR Therapeutics in the 1st quarter valued at about $31,000. Finally, Allworth Financial LP boosted its holdings in CRISPR Therapeutics by 443.8% in the 1st quarter. Allworth Financial LP now owns 609 shares of the company’s stock valued at $38,000 after purchasing an additional 497 shares during the last quarter. 56.12% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.